Scientists at St Georges, University of London, UK, are crowdfunding to raise funds for a phase II trial in 140 bowel cancer patients. They are repurposing Artesunate, the antimalarial drug discovered by Nobel Prize Laureate (2015) Tu Youyou, in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.
The initial target of £50,000 was reached in a record 45 days! Thank you to everyone for your support. The researchers are using the money to top-up funds they have already received from Bowel Disease UK.
There are now a few days left for Professor Krishna and his team to raise the funds needed for their Bowel Cancer clinical trial. Our community has been instrumental in getting the campaign to this point – we now need your support for the final phase.
The researchers are hoping to raise additional funds to:
1. Recruit more sites and patients to deliver results quickly
2. Apply the latest techniques and technology for early detection of recurrent tumors
3. To make the research a global collaborative study
Please can you support this vital research by backing the research and telling your friends, family and colleagues.
Campaign page
Can Artesunate, an antimalarial drug, provide an effective and affordable treatment for Bowel Cancer: futsci.com
The amazing public response to crowdfunding as novel way of supporting medical research confirms our belief that connecting the scientific community with the people that matter is vital for taking science forward.
The success of the Bowel Cancer campaign shows what can be achieved when communities connect with each other. Our vision at FutSci is for scientists and the public to have an open dialogue, everyone knows who and what they are funding.
The truly outstanding public response to crowdfund the repurposing of Artesunate in Bowel Cancer demonstrates the importance of engaging both the scientific and public communities.
Please Help Us Crowdfund Research for a Safe, Affordable Treatment to Beat Bowel Cancer by visiting www.futsci.com and supporting this vital research.
